Workshop Report: FDA Workshop on Improving Cardiotoxicity Assessment With Human-Relevant Platforms
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Given that cardiovascular safety concerns remain the leading cause of drug attrition at the preclinical drug development stage, the National Center for Toxicological Research of the US Food and Drug Administration hosted a workshop to discuss current gaps and challenges in translating preclinical cardiovascular safety data to humans. This white paper summarizes the topics presented by speakers from academia, industry, and government intended to address the theme of improving cardiotoxicity assessment in drug development. The main conclusion is that to reduce cardiovascular safety liabilities of new therapeutic agents, there is an urgent need to integrate human-relevant platforms/approaches into drug development. Potential regulatory applications of human-derived cardiomyocytes and future directions in employing human-relevant platforms to fill the gaps and overcome barriers and challenges in preclinical cardiovascular safety assessment were discussed. This paper is intended to serve as an initial step in a public-private collaborative development program for human-relevant cardiotoxicity tools, particularly for cardiotoxicities characterized by contractile dysfunction or structural injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450
Structural and Functional Maturation of Cardiomyocytes Derived from Human Pluripotent Stem Cells
Lundy, S. D., Zhu, W.-Z., Regnier, M., & Laflamme, M. A. (2013) · Stem Cells and Development · doi:10.1089/scd.2012.0490 · Cited by 738
Development of a drug screening platform based on engineered heart tissue
Hansen, A., Eder, A., Bönstrup, M., Flato, M., Mewe, M., Schaaf, S., Aksehirlioglu, B., Schwörer, A., Uebeler, J., & Eschenhagen, T. (2010) · Circulation Research · doi:10.1161/circresaha.109.211458 · Cited by 510
Sala, L., van Meer, B. J., Tertoolen, L. G. J., Bakkers, J., Bellin, M., Davis, R. P., Denning, C., Dieben, M. A. E., Eschenhagen, T., Giacomelli, E., et al. (2018) · Circulation Research · doi:10.1161/circresaha.117.312067 · Cited by 416
Sharma, A., Burridge, P. W., McKeithan, W. L., Serrano, R., Shukla, P., Sayed, N., Churko, J. M., Kitani, T., Wu, H., Holmström, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2584 · Cited by 404
Self-citationDenning, C., Borgdorff, V., Crutchley, J., Firth, K. S. A., George, V., Kalra, S., Kondrashov, A., Hoang, M. D., Mosqueira, D., Patel, A., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.10.014 · Cited by 293
Cardiac spheroids as promising in vitro models to study the human heart microenvironment
Polonchuk, L., Chabria, M., Badi, L., Hoflack, J.-C., Figtree, G., Davies, M. J., & Gentile, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-06385-8 · Cited by 223
Monticello, T. M., Jones, T. W., Dambach, D. M., Potter, D. M., Bolt, M. W., Liu, M., Keller, D. A., Hart, T. K., & Kadambi, V. J. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.09.006 · Cited by 186
Mechanism-based facilitated maturation of human pluripotent stem cell-derived cardiomyocytes
Lieu, D. K., Fu, J.-D., Chiamvimonvat, N., Tung, K. C., McNerney, G. P., Huser, T., Keller, G., Kong, C.-W., & Li, R. A. (2013) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.111.973420 · Cited by 179
Physical developmental cues for the maturation of human pluripotent stem cell-derived cardiomyocytes
Zhu, R., Blazeski, A., Poon, E., Costa, K. D., Tung, L., & Boheler, K. R. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt507 · Cited by 110
Cited by
Functional isolation, culture and cryopreservation of adult human primary cardiomyocytes
Zhou, B., Shi, X., Tang, X., Zhao, Q., Wang, L., Yao, F., Hou, Y., Wang, X., Feng, W., Wang, L., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01044-5 · Cited by 46
“As such, the US Food and Drug Administration is moving towards including hPCMs as a human-relevant platform in the drug discovery pipeline.(22) However, current hPCM-based studies are restricted to the use of acutely isolated cells, and are limited in cell number, because reliable and reproducible methods for hPCM iso…”
BackgroundQu, Y., Li, T., Liu, Z., Li, D., & Tong, W. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103770 · Cited by 41
Population-based high-throughput toxicity screen of human iPSC-derived cardiomyocytes and neurons
Huang, C. Y., Nicholson, M. W., Wang, J. Y., Ting, C. Y., Tsai, M. H., Cheng, Y. C., Liu, C. L., Chan, D. Z. H., Lee, Y. C., Hsu, C. C., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110643 · Cited by 36
Self-citation
Metadata
- Authors
- Pang, L., Sager, P., Yang, X., Shi, H., Sannajust, F., Brock, M., Wu, J. C., Abi-Gerges, N., Lyn-Cook, B., Berridge, B. R., & Stockbridge, N.
- Venue
- Circulation Research
- Published
- 2019-10-11
- Volume
- 125
- Issue
- 9
- Pages
- 855-867
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2979409238
- Cited by
- 73
- References
- 13
- FWCI
- 10.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Workshop Report: FDA Workshop on Improving Cardiotoxicity Assessment With Human-Relevant Platforms. https://app.cochat.ai/papers/10.1161/circresaha.119.315378
- The paper
- Pang, L., Sager, P., Yang, X., Shi, H., Sannajust, F., Brock, M., Wu, J. C., Abi-Gerges, N., Lyn-Cook, B., Berridge, B. R., & Stockbridge, N. (2019). Workshop Report: FDA Workshop on Improving Cardiotoxicity Assessment With Human-Relevant Platforms. Circulation Research. https://doi.org/10.1161/circresaha.119.315378
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.